Personalized cancer vaccine strategy elicits polyfunctional T cells and demonstrates clinical benefits in ovarian cancer

Abstract T cells are important for controlling ovarian cancer (OC). We previously demonstrated that combinatorial use of a personalized whole-tumor lysate-pulsed dendritic cell vaccine (OCDC), bevacizumab (Bev), and cyclophosphamide (Cy) elicited neoantigen-specific T cells and prolonged OC survival...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Janos L. Tanyi, Cheryl L.-L. Chiang, Johanna Chiffelle, Anne-Christine Thierry, Petra Baumgartener, Florian Huber, Christine Goepfert, David Tarussio, Stephanie Tissot, Drew A. Torigian, Harvey L. Nisenbaum, Brian J. Stevenson, Hajer Fritah Guiren, Ritaparna Ahmed, Anne-Laure Huguenin-Bergenat, Emese Zsiros, Michal Bassani-Sternberg, Rosemarie Mick, Daniel J. Powell, George Coukos, Alexandre Harari, Lana E. Kandalaft
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Immunologic diseases. Allergy RC581-607 Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/ba1d3a5199c64080b68ad63708532dda
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Sea el primero en dejar un comentario!

Personalized cancer vaccine strategy elicits polyfunctional T cells and demonstrates clinical benefits in ovarian cancer

Ejemplares similares